Literature DB >> 12084343

Prostatic intraepithelial neoplasia.

D G Bostwick1.   

Abstract

High-grade prostatic intraepithelial neoplasia (PIN) is now accepted as the most likely pre-invasive stage of adenocarcinoma, a decade after its first formal description. PIN has a high predictive value as a marker for adenocarcinoma, and its identification warrants repeat biopsy for concurrent or subsequent invasive carcinoma. The only method of detection is biopsy; PIN does not significantly elevate serum prostate-specific antigen concentration or its derivatives and cannot be detected by ultrasound. Most studies suggest that most patients with PIN will develop carcinoma within 10 years. PIN is associated with progressive abnormalities of phenotype and genotype that are similar to cancer rather than normal prostatic epithelium, indicating impairment of cell differentiation with advancing stages of prostatic carcinogenesis. Androgen deprivation therapy decreases the prevalence and extent of PIN, suggesting that this form of treatment may play a role in chemoprevention.

Entities:  

Mesh:

Year:  2000        PMID: 12084343     DOI: 10.1007/s11934-000-0037-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  46 in total

1.  Evidence of independent origin of multiple tumors from patients with prostate cancer.

Authors:  L Cheng; S Y Song; T G Pretlow; F W Abdul-Karim; H J Kung; D V Dawson; W S Park; Y W Moon; M L Tsai; W M Linehan; M R Emmert-Buck; L A Liotta; Z Zhuang
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

2.  Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.

Authors:  S D Sweat; A Pacelli; E J Bergstralh; J M Slezak; D G Bostwick
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

3.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

Authors:  H Bonkhoff; T Fixemer; I Hunsicker; K Remberger
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

Authors:  X J Yang; K Lecksell; K Short; J Gottesman; L Peterson; J Bannow; P F Schellhammer; W P Fitch; G B Hodge; R Parra; S Rouse; J Waldstreicher; J I Epstein
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

5.  Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy.

Authors:  L Cheng; J C Cheville; T M Pisansky; T J Sebo; J Slezak; E J Bergstralh; R M Neumann; R Singh; A Pacelli; H Zincke; D G Bostwick
Journal:  Am J Surg Pathol       Date:  1999-07       Impact factor: 6.394

6.  The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma.

Authors:  J Qian; P Wollan; D G Bostwick
Journal:  Hum Pathol       Date:  1997-02       Impact factor: 3.466

7.  Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.

Authors:  S Kasper; P C Sheppard; Y Yan; N Pettigrew; A D Borowsky; G S Prins; J G Dodd; M L Duckworth; R J Matusik
Journal:  Lab Invest       Date:  1998-03       Impact factor: 5.662

8.  Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate.

Authors:  F J Skjørten; A Berner; S Harvei; T E Robsahm; S Tretli
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

9.  Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy.

Authors:  D Shepherd; D W Keetch; P A Humphrey; D S Smith; D Stahl
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

Review 10.  The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.

Authors:  D G Bostwick; H B Burke; T M Wheeler; L W Chung; R Bookstein; T G Pretlow; R B Nagle; R Montironi; M M Lieber; R W Veltri
Journal:  J Cell Biochem Suppl       Date:  1994
View more
  12 in total

1.  Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung.

Authors:  Reinhard Ullmann; Massimo Bongiovanni; Iris Halbwedl; Susanna Petzmann; Margit Gogg-Kammerer; Anna Sapino; Mauro Papotti; Gianni Bussolati; Helmut H Popper
Journal:  Virchows Arch       Date:  2003-04-09       Impact factor: 4.064

Review 2.  High grade prostatic intraepithelial neoplasia is a disease.

Authors:  M S Steiner
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

3.  Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.

Authors:  Aldo V Bono; Roberta Mazzucchelli; Ilaria Ferrari; Antonio Lopez-Beltran; Andrea B Galosi; Liang Cheng; Rodolfo Montironi
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

4.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Authors:  Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

Review 5.  Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

Authors:  Jeroen Kneppers; Andries M Bergman; Wilbert Zwart
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 6.  High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction.

Authors:  Mitchell S Steiner
Journal:  World J Urol       Date:  2003-02-21       Impact factor: 4.226

7.  Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors.

Authors:  Wang Cheung; Marlene M Darfler; Hector Alvarez; Brian L Hood; Thomas P Conrads; Nils Habbe; David B Krizman; Jan Mollenhauer; Georg Feldmann; Anirban Maitra
Journal:  Pancreatology       Date:  2008-10-13       Impact factor: 3.996

8.  TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Authors:  Orla M Casey; Lei Fang; Paul G Hynes; Wassim G Abou-Kheir; Philip L Martin; Heather S Tillman; Gyorgy Petrovics; Hibah O Awwad; Yvona Ward; Ross Lake; Luhua Zhang; Kathleen Kelly
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

Review 9.  The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.

Authors:  Bandana Chatterjee
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation.

Authors:  Alexandros Papachristodoulou; Aditya Dutta; Antonio Rodriguez-Calero; Sukanya Panja; Elizabeth Margolskee; Renu K Virk; Teresa A Milner; Luis Pina Martina; Jaime Y Kim; Matteo Di Bernardo; Alanna B Williams; Elvis A Maliza; Joseph M Caputo; Christopher Haas; Vinson Wang; Guarionex Joel De Castro; Sven Wenske; Hanina Hibshoosh; James M McKiernan; Michael M Shen; Mark A Rubin; Antonina Mitrofanova; Cory Abate-Shen
Journal:  Cancer Discov       Date:  2021-04-23       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.